Evidence map›Paper›PMID 30352606›Full record

ReviewMolecular cancer2018

Therapeutic advances in anaplastic thyroid cancer: a current perspective.

Shikha Saini, Kiara Tulla, Ajay V Maker, Kenneth D Burman, Bellur S Prabhakar

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05819593 (A Critical Analysis of Anaplastic Thyroid Clinical Trials), which is not on this map. Cited by 132 papers.

0numbers the graph read from it
0cells of the map it votes in
132citing papers in PubMed
17.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05819593 unknown statusnot on this mapstarted 2024, after this paper: background citation

A Critical Analysis of Anaplastic Thyroid Clinical Trials: Perspectives From Patient Experiences

TypeobservationalSponsorPower Life Sciences Inc.Ran2024 to 2026Enrolled500ConditionsAnaplastic Thyroid Cancer
3 · Its place in the literature

Who cites it

132 citing papers in PubMed, 264 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

72 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Shikha SainiDepartment of Microbiology and Immunology, University of Illinois-College of Medicine, Chicago, IL, USA.
Kiara TullaDepartment of Surgery, Division of Surgical Oncology, University of Illinois-College of Medicine, Chicago, IL, USA.
Ajay V MakerDepartment of Microbiology and Immunology, University of Illinois-College of Medicine, Chicago, IL, USA.
Kenneth D BurmanMedStar Washington Hospital Medical Center, Washington, DC, USA.
Bellur S PrabhakarDepartment of Microbiology and Immunology, University of Illinois-College of Medicine, Chicago, IL, USA. bprabhak@uic.edu.ORCID 0000-0001-9815-9850
University of Illinois Urbana-Champaign · USIllinois College · USWashington Hospital · US

Funding

Overcoming Therapeutic Resistance in Anaplastic Thyroid CancerI01BX002285 · VA · JESSE BROWN VA MEDICAL CENTER · PI PRABHAKAR, BELLUR S · 2015 to 2019
–
BLRD VA I01 BX002285
6 · The paper itself

Abstract

Thyroid cancer incidence is increasing at an alarming rate, almost tripling every decade. In 2017, it was the fifth most common cancer in women. Although the majority of thyroid tumors are curable, about 2-3% of thyroid cancers are refractory to standard treatments. These undifferentiated, highly aggressive and mostly chemo-resistant tumors are phenotypically-termed anaplastic thyroid cancer (ATC). ATCs are resistant to standard therapies and are extremely difficult to manage. In this review, we provide the information related to current and recently emerged first-line systemic therapy (Dabrafenib and Trametinib) along with promising therapeutics which are in clinical trials and may be incorporated into clinical practice in the future. Different categories of promising therapeutics such as Aurora kinase inhibitors, multi-kinase inhibitors, epigenetic modulators, gene therapy using oncolytic viruses, apoptosis-inducing agents, and immunotherapy are reviewed. Combination treatment options that showed synergistic and antagonistic effects are also discussed. We highlight ongoing clinical trials in ATC and discuss how personalized medicine is crucial to design the second line of treatment. Besides using conventional combination therapy, embracing a personalized approach based on advanced genomics and proteomics assessment will be crucial to developing a tailored treatment plan to improve the chances of clinical success.

Indexed as

AnimalsCombined Modality TherapyDisease ManagementHumansThyroid Carcinoma, AnaplasticTreatment OutcomeAnaplastic thyroid CancerClinical trialImmunotherapyInhibitorsTherapeuticsTumor

Identifiers

PMID30352606
PMCPMC6198524
OpenAlexW2895923730

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.